Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells
Objective: There is a need to develop alternative Push therapeutic strategies to overcome cisplatin-associated resistance in patients with ovarian cancer.Histone deacetylation (HDAC) associated with inactivation of genes has been implicated in the epigenetic silencing of tumor suppressor genes affecting critical biological activities in cancer cell